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Sir,
Both single-arm studies (Di Fiore et al, 2007; Lie `vre et al, 2008)
and randomised clinical trials (Amado et al, 2008; Karapetis et al,
2008) for the treatment of metastatic colorectal cancer (mCRC)
with anti-EGFR monoclonal antibodies (mAbs) have unambi-
guously demonstrated that the occurrence of somatic KRAS
mutations is a highly predictive marker of resistance to such
therapies. Based on these data, analysis of KRAS mutation status in
mCRC patients is now routinely carried out to select candidates for
anti-EGFR treatment. However, it is still a matter of debate which
KRAS codons should be investigated and which genotyping
methods should be used.
To date, all of the reported studies focused on the analysis of
missense KRAS mutations in codon 12 and 13. Indeed, substitu-
tions at these codons (i) represent up to 90% of KRAS alterations
found in colorectal cancer (Forbes et al, 2009), (ii) result in the
accumulation of the protein in the active GTP-bound conforma-
tion (Malumbres and Barbacid, 2003) and (iii) impair the
therapeutic effect of anti-EGFR mAb. Nevertheless, the recent
data reported by Loupakis et al (2009) showed that rare mutations
occurring at codon 61 or 146 are clinically relevant and predict
resistance to cetuximab and irinotecan treatment. Furthermore,
according to our personal experience, in a series of 845 surgical
samples from mCRC patients, who were referred to our institution
for diagnosis of KRAS mutations, the analysis by high-resolution
melting (HRM) followed by bi-directional direct sequencing
of exon 2 identified 307 (36.33%) mutated samples, among which
12 showed rare variants. Six tumours carried rare codon 13
substitutions (five c.37G4T, p.G13C and one c.37C4G, p.G13R).
Four tumours presented double-point mutations (two patients
had the c.38_39GC4AA, p.G13E modification, one patient the
c.34_35GG4CT, p.G12A modification and one patient the
c.34_35GG4TT, p.G12F modification) and two patients showed
two uncommon KRAS mutations. The first one was an in-frame
c.30_31 insGGA insertion resulting in a glycine insertion
(p.G10_A11insG) in a rectal lesion located 7cm from the anal
verge of a 74-year-old man. Histological examination classified
this tumour as well differentiated with a T3NxM1 stage. This
uncommon mutation has only been previously reported in one
CRC (Simi et al, 2008) patient and in a case of childhood myeloid
leukaemia (Bollag et al, 1996). This duplication has been shown to
induce cellular transformation in vitro and activation of the
RAS–MAPK signalling pathway linked to impaired intrinsic GTP
hydrolysis and resistance to GAPs (Bollag et al, 1996). Based
on these data, the presence of this KRAS variant could be supposed
to predict resistance to anti-EGFR therapies. The second
uncommon KRAS mutation was a heterozygous 6-bp in-frame
c.36_37insGCTGGT insertion that was responsible for the insertion
of both one extra alanine and one extra glycine (p.G12_G13insAG).
This mutation was found in a hepatic metastasis lesion from a
65-year-old man with a sigmoid colon cancer. To the best of our
knowledge, this tandem duplication of both codon 12 and 13 has
not been described before in any cancer type. Although the
functional characterisation of this insertional variant is not
available, previous in vitro data (Klockow et al, 2000) have
reported that synthetic mutants showing insertions of extra amino
acids in the KRAS codon 10–17 region (phosphate-binding loop)
can promote cellular outgrowth and stimulate the MAP-kinase
pathway more efficiently than the common oncogenic p.G12V
variant. Thus, also the specific alteration found in this patient
could possibly be associated with resistance to anti-EGFR therapy.
Together, these data showed the clinical necessity to investigate
the presence of rare or complex KRAS variants in mCRC patients
before anti-EGFR therapy decision. Moreover, the occurrence of
these allelic variants has certainly been underestimated, because
many laboratories or commercial KRAS detection solutions focus
only on the analysis of seven hotspots corresponding to amino-
acid changes G12D, G12V, G12C, G12S, G12A, G12R and G13D.
Particularly, these additional mutations have an impact on both
therapeutic decision-making and molecular testing. We believe
that in the absence of (i) KRAS standardised testing procedures
and (ii) sufficient data on the functional role of rare variants, a
comprehensive analysis to identify all KRAS mutations in tumour
samples is required.
At the present time, no ideal mutation testing method is in
use universally for KRAS status determination (Jimeno et al, 2009).
To circumvent KRAS mutation targeting, we propose a two-step
diagnostic approach. First, an exhaustive analysis through
genetic screening of exon 2 and 3 could be carried out by HRM
(Wittwer et al, 2003). Then, for exons with an altered melting
profile, characterisation of the KRAS variants by sequencing
could be performed. In addition, the use of traditional PCR
could be replaced by coamplification at lower denaturation Published online 16 February 2010
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www.bjcancer.comtemperature-PCR (Li et al, 2008) to reach the detection of low-level
somatic mutations that characterise heterogeneous or stromal
contaminated samples.
We therefore suggest taking into account the occurrence of rare
KRAS gene substitutions or more complex alterations for a more
accurate patient selection for anti-EGFR therapies. A compre-
hensive detection of these alterations is not an inaccessible
summit. The rapid, reliable, comprehensive and cost-limited
two-step approach we propose is relatively easy to implement
without any waste of time or money.
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